Incyte Announces Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream In Patients With Atopic Dermatitis; PRimary And Secondary Endpoints Met In Both TRuE-AD1 And TRuE-AD2
Benzinga Newsdesk